Naphthalene Derivatives Melatonin Receptor Affinity

The patent applies parameter changes by modifying the chemical structure of melatonin analogues through systematic variation of substituents at positions 1, 2, 6, and 7 of the indole ring, as well as modifications of the side chain at position 3. These structural parameter changes result in compounds with enhanced metabolic stability and extended half-life while maintaining or improving receptor affinity, directly resolving the contradiction between duration of action and metabolic stability

The invention employs composite molecular structures combining the core melatonin scaffold with various substituent groups (halogens, alkyl chains, hydroxyl groups, methoxy groups) to create hybrid compounds that exhibit both improved metabolic stability and prolonged duration of action. The composite nature of these analogues allows optimization of both pharmacokinetic properties simultaneously

The patent applies segmentation by dividing the receptor binding interaction into distinct structural components: the core indole moiety for general melatonin receptor binding, and specific substituent patterns (such as 6-ethyl-7-methoxy substitution or 1-alkyl groups) that confer selectivity for MT1 versus MT2 subtypes. This modular approach allows systematic optimization of selectivity without requiring complete redesign of the molecular framework

The invention implements local quality by introducing specific functional groups at particular positions on the indole ring to achieve receptor subtype selectivity. For example, adding a hydroxyl group at position 6 or specific alkyl groups at position 1 creates local structural features that interact with specific amino acid residues in MT1 or MT2 receptors, thereby achieving selectivity through localized structural modifications rather than global changes